Coronary artery disease (CAD) is prevalent throughout the world, with a significant impact
on global health. There is a vast collection of data in the medical literature relating to the …

Purpose of review The optimal duration of dual antiplatelet therapy (DAPT) has been a topic
of considerable interest in recent years, as the risk of stent thrombosis has decreased with …

Dual antiplatelet therapy has been extensively studied in the last two decades, giving
opportunities for thorough evidence-based recommendations. The ESC/EACTS guidelines …

Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease
(CAD) but there remains uncertainty as to the optimal approach for balancing an individual's …

International guidelines recommend the use of aspirin treatment immediately and
indefinitely in coronary patients. The optimal time to start and the duration of dual antiplatelet …

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at
preventing the atherothrombotic complications in patients with a variety of coronary artery …

This editorial refers to 'Modifying effect of dual antiplatelet therapy on incidence of stent
thrombosis according to implanted drug-eluting stent type'†, by E. Camenzind et al., on page …

Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of
thrombotic complications associated with atherosclerotic cardiovascular diseases. Emerging …

The choice and optimal duration of dualantiplatelet therapy (DAPT) for the treatment of
coronary artery disease (CAD) represent a challenging clinical dilemma. Antiplatelet …

The scope of the 2017 European Society of Cardiology (ESC) focused update on dual
antiplatelet therapy (DAPT) in coronary artery disease (CAD) developed in collaboration …